{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T16:23:42Z","timestamp":1792254222491,"version":"4.4.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":184,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1124\/dmd.123.001617","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T22:20:12Z","timestamp":1714170012000},"page":"606-613","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["KLF15-Cyp3a11 Axis Regulates Rifampicin-Induced Liver Injury"],"prefix":"10.1016","volume":"52","author":[{"given":"Wanqing","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ku-Geng","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengtong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuangqi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixiong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinqi","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tangxin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7883-1467","authenticated-orcid":false,"given":"Shuxin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.123.001617_bib1","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40262-019-00764-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of rifampicin in human tuberculosis","volume":"58","author":"Abulfathi","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.123.001617_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(22)00359-7","article-title":"WHO\u2019s global tuberculosis report 2022","volume":"4","author":"Bagcchi","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1124\/dmd.123.001617_bib3","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3390\/ijms17020224","article-title":"Hepatotoxicity by drugs: the most common implicated agents","volume":"17","author":"Bj\u00f6rnsson","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1124\/dmd.123.001617_bib4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/BF00558209","article-title":"Binding of rifampicin by human plasma proteins","volume":"7","author":"Boman","year":"1974","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001617_bib5","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1136\/gut.13.5.366","article-title":"Effect of rifampicin on liver function in man","volume":"13","author":"Capelle","year":"1972","journal-title":"Gut"},{"key":"10.1124\/dmd.123.001617_bib6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.taap.2009.06.022","article-title":"Altered integrity and decreased expression of hepatocyte tight junctions in rifampicin-induced cholestasis in mice","volume":"240","author":"Chen","year":"2009","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1124\/dmd.123.001617_bib7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jhep.2006.01.027","article-title":"Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice","volume":"45","author":"Chowdhury","year":"2006","journal-title":"J Hepatol"},{"key":"10.1124\/dmd.123.001617_bib8","doi-asserted-by":"crossref","first-page":"929","DOI":"10.14309\/ajg.0000000000000201","article-title":"Drug-induced acute-on-chronic liver failure in Asian patients","volume":"114","author":"Devarbhavi","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1124\/dmd.123.001617_bib9","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.tube.2011.02.004","article-title":"The pharmacokinetics and pharmacodynamics of rifampicin in adults and children in relation to the dosage recommended for children","volume":"91","author":"Donald","year":"2011","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1124\/dmd.123.001617_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01910-17","article-title":"Tuberculosis: just the FAQs","volume":"8","author":"Guinn","year":"2017","journal-title":"MBio"},{"key":"10.1124\/dmd.123.001617_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yjmcc.2007.04.005","article-title":"Kruppel-like factors (KLFs) in muscle biology","volume":"43","author":"Haldar","year":"2007","journal-title":"J Mol Cell Cardiol"},{"key":"10.1124\/dmd.123.001617_bib12","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s42255-019-0054-7","article-title":"KLF15 regulates endobiotic and xenobiotic metabolism","volume":"1","author":"Han","year":"2019","journal-title":"Nat Metab"},{"key":"10.1124\/dmd.123.001617_bib13","doi-asserted-by":"crossref","first-page":"7231","DOI":"10.1038\/ncomms8231","article-title":"Circadian control of bile acid synthesis by a KLF15-Fgf15 axis","volume":"6","author":"Han","year":"2015","journal-title":"Nat Commun"},{"key":"10.1124\/dmd.123.001617_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1022809","article-title":"Involvement of endoplasmic reticulum stress in rifampicin-induced liver injury","volume":"13","author":"Hou","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1124\/dmd.123.001617_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153412","article-title":"Naringenin alleviates nonalcoholic steatohepatitis in middle-aged Apoe-\/-mice: role of SIRT1","volume":"81","author":"Hua","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1124\/dmd.123.001617_bib16","first-page":"893","article-title":"Quercetin protects against atherosclerosis by regulating the expression of PCSK9, CD36, PPAR\u03b3, LXR\u03b1 and ABCA1","volume":"44","author":"Jia","year":"2019","journal-title":"Int J Mol Med"},{"key":"10.1124\/dmd.123.001617_bib17","first-page":"13","article-title":"[Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis]","volume":"83","author":"Kaneko","year":"2008","journal-title":"Kekkaku"},{"key":"10.1124\/dmd.123.001617_bib18","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1210\/er.2001-0038","article-title":"The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism","volume":"23","author":"Kliewer","year":"2002","journal-title":"Endocr Rev"},{"key":"10.1124\/dmd.123.001617_bib19","first-page":"1079","article-title":"Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis","volume":"1","year":"1972","journal-title":"Lancet"},{"key":"10.1124\/dmd.123.001617_bib20","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1172\/JCI3703","article-title":"The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions","volume":"102","author":"Lehmann","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1124\/dmd.123.001617_bib21","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nm.3104","article-title":"Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy","volume":"19","author":"Li","year":"2013","journal-title":"Nat Med"},{"key":"10.1124\/dmd.123.001617_bib22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF02152772","article-title":"Desacetyl-rifamycins: preparation and antibacterial properties","volume":"24","author":"Maggi","year":"1968","journal-title":"Experientia"},{"key":"10.1124\/dmd.123.001617_bib23","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s12072-008-9085-y","article-title":"A prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases","volume":"2","author":"Makhlouf","year":"2008","journal-title":"Hepatol Int"},{"key":"10.1124\/dmd.123.001617_bib24","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1152\/physrev.00058.2009","article-title":"Mammalian Kr\u00fcppel-like factors in health and diseases","volume":"90","author":"McConnell","year":"2010","journal-title":"Physiol Rev"},{"key":"10.1124\/dmd.123.001617_bib25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-1-59745-201-4_6","article-title":"Hepatocyte apoptosis","volume":"481","author":"Najimi","year":"2009","journal-title":"Methods Mol Biol"},{"key":"10.1124\/dmd.123.001617_bib26","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1378\/chest.61.6_Supplement.589","article-title":"Antituberculosis activity of rifampin. Report of studies performed and in progress (1966\u20131971)","volume":"61","author":"Nitti","year":"1972","journal-title":"Chest"},{"key":"10.1124\/dmd.123.001617_bib27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cca.2007.11.028","article-title":"Isoniazid-rifampicin induced lipid changes in rats","volume":"389","author":"Pal","year":"2008","journal-title":"Clin Chim Acta"},{"issue":"Suppl 3","key":"10.1124\/dmd.123.001617_bib28","article-title":"History of the development of rifampin","volume":"5","author":"Sensi","year":"1983","journal-title":"Rev Infect Dis"},{"key":"10.1124\/dmd.123.001617_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00210-17","article-title":"Genetic determinants of the pharmacokinetic variability of rifampin in malawian adults with pulmonary tuberculosis","volume":"61","author":"Sloan","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.123.001617_bib30","doi-asserted-by":"crossref","first-page":"11700","DOI":"10.1080\/21655979.2021.2003930","article-title":"Study on the associations between liver damage and antituberculosis drug rifampicin and relative metabolic enzyme gene polymorphisms","volume":"12","author":"Su","year":"2021","journal-title":"Bioengineered"},{"key":"10.1124\/dmd.123.001617_bib31","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/cpt.778","article-title":"A population pharmacokinetic model incorporating saturable pharmacokinetics and autoinduction for high rifampicin doses","volume":"103","author":"Svensson","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001617_bib32","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1440-1746.2007.05207.x","article-title":"Antituberculosis drug-induced hepatotoxicity: concise up-to-date review","volume":"23","author":"Tostmann","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1124\/dmd.123.001617_bib33","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nrgastro.2011.22","article-title":"Mechanisms of drug-induced liver injury: from bedside to bench","volume":"8","author":"Tujios","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1124\/dmd.123.001617_bib34","first-page":"141","article-title":"Protective effects of vitamin C and NAC on the toxicity of rifampin on Hepg2 cells","volume":"12","author":"Vahdati-Mashhadian","year":"2013","journal-title":"Iran J Pharm Res"},{"key":"10.1124\/dmd.123.001617_bib35","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/cir184","article-title":"Why do we use 600 mg of rifampicin in tuberculosis treatment?","volume":"52","author":"van Ingen","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1124\/dmd.123.001617_bib36","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/jac\/33.3.387","article-title":"Hepatic side-effects of antibiotics","volume":"33","author":"Westphal","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/dmd.123.001617_bib37","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijmyco.2015.10.002","article-title":"Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: a cohort study","volume":"5","author":"Wondwossen","year":"2016","journal-title":"Int J Mycobacteriol"},{"key":"10.1124\/dmd.123.001617_bib39","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1440-1843.2006.00941.x","article-title":"Antituberculosis drugs and hepatotoxicity","volume":"11","author":"Yew","year":"2006","journal-title":"Respirology"},{"key":"10.1124\/dmd.123.001617_bib40","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1128\/AAC.05149-11","article-title":"Effect of rifampin on production of inflammatory mediators in HepG2 liver epithelial cells","volume":"55","author":"Yuhas","year":"2011","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624007050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624007050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.123.001617","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T08:50:59Z","timestamp":1739955059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624007050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0090955624007050"],"URL":"https:\/\/doi.org\/10.1124\/dmd.123.001617","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KLF15-Cyp3a11 Axis Regulates Rifampicin-Induced Liver Injury","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.123.001617","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The Author(s)","name":"copyright","label":"Copyright"}]}}